# CASI Pharmaceuticals

CASI Pharmaceuticals is an Asset Manager based in Beijing, China.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Beijing, China
- **Region:** Asia
- **Address:** Beijing, China
- **Founded:** 1991
- **Assets under management:** Undisclosed
- **Website:** casipharmaceuticals.com
- **LinkedIn:** https://www.linkedin.com/company/casi-pharmaceuticals-inc

## Regulatory record

- **Reports private funds:** No

## About

CASI Pharmaceuticals was founded in 1991 and is led by Chairman and CEO Wei-Wu He, a Chinese-American scientist-entrepreneur who previously founded OriGene Technologies. The company operates a dual-headquarters model with a commercial team in Beijing and a business-development and investor-facing office in Rockville, Maryland. This trans-Pacific architecture defines its operating model: sourcing U.S. and European biotech assets that are deprioritized by their originators and commercializing them for the China market through a Beijing-based hematology-oncology sales force. The firm's strategy centers on acquiring or in-licensing late-stage and commercial hematology-oncology therapeutics with established clinical data, then registering, manufacturing, and distributing them in China. Its commercial portfolio includes EVOMELA (melphalan for injection), an conditioning agent used in stem cell transplantation in multiple myeloma patients, in-licensed from Spectrum Pharmaceuticals. The pipeline has included assets like CID-103, an anti-CD38 monoclonal antibody for multiple myeloma, and BI-1206, an anti-FcγRIIB antibody. CASI deploys capital through direct asset acquisitions, regional licensing deals, and co-development agreements rather than traditional fund structures, with the geographic scope heavily concentrated on Greater China. The company employs a lean operating model, carrying a commercial team in China supported by corporate functions in Maryland. In November 2024, CASI received notification from Nasdaq regarding non-compliance with the minimum market value of listed securities requirement, adding to ongoing exchange listing pressures (per public filings, 2024). Under He's continued leadership, the firm has undergone multiple restructurings aimed at preserving cash and focusing the pipeline on near-term revenue-generating assets. CASI's fundamental structural feature is its role as a cross-border regulatory and commercial bridge. Unlike a venture-stage biotech that builds around scientific platforms, CASI acts as a China-market access channel for de-risked Western assets. This requires fluency in U.S. and Chinese drug-registration pathways, local GMP manufacturing partnerships, and a direct hospital sales force — a bundled capability set that is difficult for Western biotechs to replicate independently without building their own China infrastructure.

## Sectors

- Biotech
- Oncology

## Offices

- Rockville, Maryland, United States

## People

- Wei-Wu He — Chairman & CEO

## Questions

### Who runs investment and strategic decisions at CASI Pharmaceuticals?

Chairman and CEO Wei-Wu He has led CASI since 2012. He holds an MD from Peking Union Medical College and a PhD from the University of Pittsburgh, and previously founded OriGene Technologies. Day-to-day asset-sourcing and business-development decisions involve U.S.-based leadership in Rockville, Maryland, while commercial execution is run from Beijing.

### How does CASI source the assets it commercializes?

CASI acquires or in-licenses late-stage and already-approved hematology-oncology drugs from Western biotech companies that have deprioritized those programs. The company then handles China-specific clinical bridging studies, regulatory registration, local GMP manufacturing arrangements, and hospital distribution through its own Beijing commercial team.

### Does CASI develop its own drugs or only commercialize in-licensed assets?

CASI's primary model is in-licensing and commercialization. Its commercial portfolio has included EVOMELA, in-licensed from Spectrum Pharmaceuticals. The pipeline has included CID-103, an anti-CD38 monoclonal antibody, and BI-1206, an anti-FcγRIIB antibody, both acquired through licensing deals rather than internal discovery.

### What is CASI's geographic focus?

The firm operates almost exclusively in Greater China, with a commercial sales force in Beijing focused on hematology-oncology hospital accounts. Its U.S. presence in Rockville, Maryland, handles corporate functions, investor relations, and business development sourcing but does not commercialize products in the U.S. market.

### What therapeutic areas does CASI target?

CASI focuses exclusively on hematology-oncology. Its commercial product, EVOMELA, is used as a conditioning agent in autologous stem cell transplantation for multiple myeloma. Pipeline assets have targeted multiple myeloma and other hematologic malignancies.

## Related profiles

- [Interactive Strength, Inc.](https://altss.com/profile/interactive-strength-inc)
- [Silexion Therapeutics Corp](https://altss.com/profile/silexion-therapeutics-corp)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/casi-pharmaceuticals-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology